ArticleWorld journal of microbiology & biotechnology2026
Engineering peroxisomal cofactor systems in Saccharomyces cerevisiae for enhanced biosynthesis of α-humulene.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
With the rapid development of synthetic biology and metabolic engineering, compartmentalized biosynthesis of natural products has attracted extensive attention, in which peroxisomes present unique advantages over other subcellular organelles. Herein, the peroxisomes cofactor balance was systematically engineered in Saccharomyces cerevisiae BY4741 to achieve efficient biosynthesis of α‑humulene. Firstly, the cytoplasmic mevalonate (MVA) pathway and AcHS2 were targeted to peroxisomes using the ScPEX5*-oPTS1* orthogonal transport system, resulting in strain LM07 with an α-humulene titer of 978.92 mg/L. Subsequently, co-expression of POX1 and FOX2 enhanced peroxisomal acetyl-CoA supply, knockout of MDH3 increased NADH availability, and overexpression of PCD1, Cv1693, PXN, and ANT1 established a peroxisomal CoA metabolic cycle, which increased the titer by 47.97% to 1448.46 mg/L. Furthermore, we conducted a screening of α-humulene synthases from different sources and enhanced the α-humulene titer in yeast by 110.71%. Finally, a cytoplasm-peroxisome dual-compartment engineering strategy was implemented to optimize the cytoplasmic α-humulene synthetic pathway. The engineered strain LM27 produced 2502.69 mg/L α-humulene in shake-flask fermentation. This regulatory strategy provides a valuable technical reference for the efficient biosynthesis of other terpenoids in S. cerevisiae.
Indexed as
Identifiers
42257761What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.